IA
OREX

IFG Advisory’s Orexigen Therapeutics, Inc. OREX Stock Holding History

IFG Advisory’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-49,000
Closed -$63K – 357
2017
Q4 		$63K Buy
+49,000
New +$79.8K 0.01% 321

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
OWIM
Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

IFG Advisory's OREX Position: Q1 2018 in Review

IFG Advisory sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2018, closing a stake of 49,000 shares — an estimated $63K sold.

IFG Advisory first reported a position in OREX in Q4 2017 and held it in 1 quarter. The position peaked at $63K in Q4 2017. 27 funds tracked by Wall St. Rank hold OREX as of Q1 2018.

  • IFG Advisory reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • IFG Advisory sold 49,000 Orexigen Therapeutics, Inc. shares in Q1 2018, an estimated $63K.
  • IFG Advisory first reported a position in Orexigen Therapeutics, Inc. in Q4 2017 and held it in 1 quarter.
  • IFG Advisory's Orexigen Therapeutics, Inc. position peaked at $63K in Q4 2017.
  • 27 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2018.

Based on IFG Advisory's 13F filing for Q1 2018, filed 26 Apr 2018.